Investor Presentation slide image

Investor Presentation

Repligen Snapshot We are enabling efficient, single-use, flexible manufacturing of biological drugs, providing first-to-market solutions for bioprocessing challenges $671M Revenue 2021 Bioprocessing solutions provider with differentiated technologies R REPLIGEN +45% 5-year CAGR +36% ex-COVID Growing through innovation, acquisitions, market strength ~39% Revenue 2021 from new markets (COVID & GT) ~60% mAbs Diversified customer base, across all biological drug modalities 10 Disruptive technologies since 2014 Drives innovation, first- to-market position, market leadership; accounts for ~25% of our revenue in 2021 >$8B TAM New applications Capacity expansion >1,800 employees Taking share in a robust and expanding global biologics market 3
View entire presentation